ReviewInternational urology and nephrology2025
Potential next generation markers of testicular germ cell tumors: miRNA-371a-3p.
Review in International urology and nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Comprehensive analysis of microRNA expression provides mechanistic insights into transcriptomic alteration in primary and metastatic testicular germ cell tumors.Scientific reports · 2025Article
- Efficacy and Safety of Three Cycles of TIP and Sequential High Dose Chemotherapy in Patients with Testicular Non-Seminomatous Germ Cell Tumors.Journal of clinical medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundTesticular germ cell tumors (TGCTs) account for approximately 98% of all testicular cancers, predominantly affecting young to middle-aged men. Early diagnosis and treatment result in a cure rate of over 95%. However, conventional serum tumor markers (STMs) such as alpha-fetoprotein (AFP), β-human chorionic gonadotropin (β-hCG), and lactate dehydrogenase (LDH), which are recommended by NCCN and EAU guidelines, have limited sensitivity, often below 60%, which diminishes their clinical utility. Recently, miRNA-371a-3p, an embryonic stem cell-associated microRNA, has been identified as being specifically expressed in TGCTs. This microRNA can be reliably detected in peripheral blood and fulfills all seven Lange-Winfield criterias for tumor markers. Notably, miRNA-371a-3p has demonstrated superior diagnostic, therapeutic, and follow-up capabilities compared to conventional STMs in TGCTs. Its potential to replace conventional STMs in clinical practice is already recognized in several clinical guidelines.
methodsA PubMed search using subject headings and free-text terms related to MicroRNA-371a-3p in TGCT management was conducted. Relevant references were also tracked, and key studies were reviewed based on predefined exclusion criteria.
resultsOut of 368 identified studies, 67 met inclusion criteria. These studies focused on MicroRNA-371a-3p's discovery, detection methods, diagnostic utility in TGCTs, and cost-effectiveness. First identified over a decade ago, microRNA-371a-3p is now established as a highly specific blood-based marker for TGCTs, valuable for diagnosis, monitoring, and follow-up, and more cost-effective than conventional STMs.
conclusionsMicroRNA-371a-3p is a promising, highly sensitive marker for TGCTs, offering better performance and cost efficiency than conventional STMs, likely to become the next-generation diagnostic tool for TGCTs.
Indexed as
Identifiers
39576421What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.